doi: 10.1002/dmrr.3043 18 FasanoAShea-DonohueT
About 10-15 companies are racing to launch their versions
Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation
Effervescent Fast&Up L-Carnitine promotes Fatty Acid Metabolism & Transports it to the muscles where it is burned
Semaglutide may cause nausea and fatigue, which can worsen when youre dehydrated
Although gallstones are common in obese patients, they are more common after rapid weight loss